Metasight leverages liquid biopsies for disease diagnosis, monitoring, and prognosis. Their unique approach to identifying disease signatures involves proprietary, multi-omics technology combined with population-scale serum samples and electronic health records. This approach enables robust, high-throughput, and cost-effective screening, all through a single blood test.